Anthelminthic treatment raises plasma iron levels but does not decrease the acute-phase response in Jakarta school children.
The study was conducted to investigate the impact of intestinal helminthiasis and treatment on iron status and acute phase response (APR) among urban Indonesian primary school children, aged 8-11 years old. The prevalence of helminthiasis among these children was; Ascaris lumbricoides, 81.6%; Trichuris trichiura, 88.3%; and mixed infection of A. lumbricoides and T. trichiura, 70.0%. Of 120 children enrolled in the investigation, 59 received a single 400 mg dose of albendazole, and 61 received a placebo. Ten days following treatment, the prevalence of ascariasis and trichuriasis in the treatment group diminished to 0% and 27%, respectively, and in the placebo group to 63.9% and 68.9%. Plasma iron, hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC), interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF) concentrations were determined prior to the intervention and 10 days after. Plasma iron concentrations and WBC count rose in the treatment group (p=< or =0.05) when compared to baseline status. Increases in hemoglobin concentrations observed in the treatment group 10 days post-treatment were not statistically significant. CRP, IL-1, IL-6 and TNF were found to be within normal limits for both groups both before and after treatment. ESR increased significantly in both treatment and placebo groups when compared the rates measured before treatment. These findings show that treatment with albendazole is associated not only with a decreased worm burden in school children, but also a rise in plasma iron.
Karyadi
E
E
SEAMEO-TROPMED Regional Center for Community Nutrition, University of Indonesia, Jakarta.
Gross
R
R
Sastroamidjojo
S
S
Dillon
D
D
Richards
A L
AL
Sutanto
I
I
D000210:Acute-Phase Reaction / Q000469:parasitology*; D015766:Albendazole / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology / Q000627:therapeutic use*; D001196:Ascariasis / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D017164:Ascaris lumbricoides; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D003430:Cross-Sectional Studies; D004311:Double-Blind Method; D006373:Helminthiasis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007214:Indonesia; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007501:Iron / Q000097:blood*; D007958:Leukocyte Count; D014257:Trichuriasis / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D014258:Trichuris; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000871:Anthelmintics; D006454:Hemoglobins; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D007501:Iron; D015766:Albendazole